Avalyn Pharma raises $100 million in a Series D round to develop inhaled medicines for pulmonary fibrosis, targeting effective delivery to the lungs.
PUBLIC · AVLNJul 22, 2025
Amount Raised
$100 Million
Round Type
Series D
CambridgeBiotechnologyHealthcareHealth Care
Investors
Wellington ManagementT. Rowe Price AssociatesCatalio Capital ManagementSR OneSuvretta Capital Management
Description
Avalyn Pharma has secured $100 million in a Series D funding round. The funding will be used to advance their inhaled pulmonary fibrosis medicines. The company aims to ensure the drugs reach the optimal location within the lung for effectiveness. This investment marks a significant step in their development process.
Who to call at Avalyn, and when
A new round usually means Avalyn is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Avalyn raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Avalyn, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Avalyn
Location
245 First Street, 18th Floor
Cambridge, Massachusetts, United States
About
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Avalyn raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealthcareHealth Care